Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study
Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study
复制标题
DOI：
10.1007/s12185-008-0034-2
复制
发表时间：
2008-02
影响因子：
2.1
通讯作者：
H. Tamai;H. Yamaguchi;H. Hamaguchi;F. Yagasaki;M. Bessho;Takeshi Kobayashi;H. Akiyama;H. Sakamaki;Satoshi Takahashi;A. Tojo;K. Ohmine;K. Ozawa;H. Okumura;S. Nakao;A. Arai;O. Miura;S. Toyota;S. Gomi;Y. Murai;N. Usui;K. Miyazawa;K. Ohyashiki;N. Takahashi;K. Sawada;A. Kato;K. Oshimi;K. Inokuchi;K. Dan
中科院分区：
文献类型：
--
作者：
H. Tamai;H. Yamaguchi;H. Hamaguchi;F. Yagasaki;M. Bessho;Takeshi Kobayashi;H. Akiyama;H. Sakamaki;Satoshi Takahashi;A. Tojo;K. Ohmine;K. Ozawa;H. Okumura;S. Nakao;A. Arai;O. Miura;S. Toyota;S. Gomi;Y. Murai;N. Usui;K. Miyazawa;K. Ohyashiki;N. Takahashi;K. Sawada;A. Kato;K. Oshimi;K. Inokuchi;K. Dan
为了阐明 11q23 异常的急性白血病 (AL) 成年患者的临床特征，我们对 58 名日本成年患者的数据进行了回顾性分析：其中 51 名患有急性髓系白血病 (AML)，7 名患有急性淋巴细胞白血病 (ALL)。 AML中不同融合伴侣的发生率分别为：t(9;11), 31.3%;t(11;19), 27.4%;t(6;11), 21.5%。 t(11;19)患者的发生率高于美国和欧洲患者，t(4;11)的发生率低于儿童期。结果表明，无论融合伙伴如何，11q23 异常的 AML 预后都很差。首次CR时年龄<60岁的11q23 AML患者接受同种异体造血干细胞移植（allo-HSCT）的结果比未接受allo-HSCT的患者更有利，但差异无统计学意义（DFS P= 0.322，OS P= 0.138）。这一结果表明，对于 11q23 异常的 AML 病例，在首次 CR 中可以考虑包括异基因 HSCT 在内的治疗策略。然而，需要进一步涉及大量病例的研究来评估allo-HSCT对11q23异常的成人AL的影响。
To clarify the clinical features of adult patients with acute leukemia (AL) with 11q23 abnormalities, we performed a retrospective analysis of data from 58 adult Japanese patients: 51 with acute myeloid leukemia (AML), and 7 with acute lymphoblastic leukemia (ALL). The incidences according to fusion partners in AML were:t(9;11), 31.3%;t(11;19), 27.4%;t(6;11), 21.5%. The incidence of patients witht(11;19) was higher than those in the US and Europe, and the incidence oft(4;11) was lower than that in childhood. The results indicated the poor prognosis of AML with 11q23 abnormalities regardless of the fusion partners. AML patients with 11q23 aged <60 years in the first CR who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed a more favorable outcome than those treated without allo-HSCT, although the differences were not statistically significant (P= 0.322 for DFS,P= 0.138 for OS). This result suggests that treatment strategies including allo-HSCT may be considered in the first CR in cases of AML with 11q23 abnormalities. However, further studies involving a large number of cases are required to assess the effect of allo-HSCT on adult AL with 11q23 abnormalities.